MedTrace Logo

Hyperlipidemia Therapy TERCET Zabrze Registry

NCT03065543 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25000

Last updated 2017-02-28

No results posted yet for this study

Summary

A study conducted to evaluate the efficacy of lipid-lowering therapy in patients with high and very high risk treated by interventional cardiology. Study endpoints:

1. Achievement of the target LDL-C at 1-year follow-up LDL-C \<70 mg / dl in the group of very high-risk and LDL-C \<100 mg / dL in high-risk patients
2. Assessment of the lipid profile of the severity of coronary artery disease in patients undergoing invasive diagnosis of coronary artery disease
3. Evaluation of trends in the treatment of lipid-lowering in patients in different years

Conditions

  • Hyperlipidemias
  • Secondary Prevention

Sponsors & Collaborators

  • Silesian Centre for Heart Diseases

    lead OTHER

Principal Investigators

  • Mariusz Gasior, prof.MD,PhD · 3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-01
Primary Completion
2016-12-31
Completion
2025-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065543 on ClinicalTrials.gov